|
| Press Releases |
|
 |
|
| Monday, September 14, 2015 |
|
|
Eisai to Present Latest Clinical Data on Lenvima (Lenvatinib) and Halaven (Eribulin) at European Cancer Congress |
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Lenvima and Halaven will be presented during the European Cancer Congress (ECC) 2015, taking place in Vienna, Austria, from September 25 to 29.
more info >> |
|
| Thursday, September 10, 2015 |
|
|
Drugs for Neglected Diseases initiative and Eisai to Test Drug Candidate for Eumycetoma Patients suffering from virtually no R&D for this neglected disease |
| The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases. more info >> |
|
| Friday, July 31, 2015 |
|
|
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer |
Eisai Co., Ltd. and Halozyme Therapeutics, Inc. announced today that they have signed a clinical collaboration agreement to evaluate Eisai's
anticancer agent eribulin mesylate in combination with Halozyme's investigational new drug PEGPH20 in first line HER2-negative advanced breast cancer. more info >> |
|
|
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)" |
| The Board of Directors of Eisai Co., Ltd. passed a resolution for the continuation of the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders", which was proposed by the Independent Committee of Outside Directors at its meeting held today. more info >> |
|
| Wednesday, July 29, 2015 |
|
|
Eisai's In-House Developed Novel Anticancer Agent Lenvima Receives Breakthrough Therapy Designation From U.S. Fda for Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today its U.S. subsidiary Eisai Inc. has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent Lenvima for the potential indication of advanced and/or metastatic renal cell carcinoma. more info >> |
|
| Friday, June 26, 2015 |
|
|
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for Pediatric Patients in Japan |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it will launch Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate), on June 29 in Japan. more info >> |
|
| Monday, June 22, 2015 |
|
|
U.S. FDA Approves Eisai's Antiepileptic Agent Fycompa as Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. more info >> |
|
| Monday, June 1, 2015 |
|
|
Eisai Receives European Commission Approval of Anticancer Agent Lenvima for Treatment of Advanced Thyroid Cancer Refractory to Radioactive Iodine |
| Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has received approval from the European Commission (EC) for anticancer agent Lenvima (lenvatinib mesylate) in the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hurthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). more info >> |
|
| Friday, May 29, 2015 |
|
|
AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA, a Fully Human Anti-TNF-alpha Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis |
| AbbVie GK and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of HUMIRA Pre-filled Syringe 40 mg / 0.8 mL, a fully human anti-TNF-alpha monoclonal antibody formulation, has been lifted for use in patients with ankylosing spondylitis. more info >> |
|
| Wednesday, May 27, 2015 |
|
|
Eisai Submits New Drug Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. announced today that it has submitted a new drug application for mecobalamin (development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT/SGT
|
|
|
Ceramics & Natural Stone Manufacturers Converge in Bangkok for ASEAN Ceramics & ASEAN Stone 2025
Oct 16, 2025 12:00 HKT/SGT
|
|
|
Discover the Secret to Your Best You Through Silica-Rich Hydration with Spritzer Natural Mineral Water
Oct 15, 2025 20:30 HKT/SGT
|
|
|
Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST
|
|
|
Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST
|
|
|
Standard Chartered GBA Business Confidence Indices rise to multi-year high levels
Oct 15, 2025 19:08 HKT/SGT
|
|
|
Honda to Present World Premiere of ProZision(TM) Autonomous, at Equip Exposition 2025, Honda Battery-powered Autonomous Riding Lawn Mower
Oct 15, 2025 19:56 JST
|
|
|
Honda to Make Additional Investment in U.S.-based Helm.ai to Further Enhance Development of Next-generation AD/ADAS
Oct 15, 2025 19:25 JST
|
|
|
CITIC Telecom CPC Strengthens 'AI+ Cloud Network Security' Framework 'New MiiND for a Connected Future Beyond AI+ Security'
Oct 15, 2025 17:57 HKT/SGT
|
|
|
MHI Thermal Systems Wins 2025 GOOD DESIGN AWARD for Hyper Multi LXZ Series of Building-Use Multi-Split Air-Conditioners in Japan
Oct 15, 2025 18:50 JST
|
|
|
Focus Graphite Appoints Jean-Francois Perrault as Strategic Advisor
Oct 15, 2025 17:09 HKT/SGT
|
|
|
PCG Selected as e-Payment Service Provider for China Resources' 'Charge Wonderful Life,' Expanding Payment Services for Car Parks and EV Charging to Promote Green, Smart Mobility
Oct 15, 2025 14:30 HKT/SGT
|
|
|
Graid Technology Announces Strategic License Agreement With Intel Corporation to Accelerate RAID Innovation
Oct 15, 2025 00:00 HKT/SGT
|
|
|
GA-ASI and Hanwha Finalize Deal To Produce Gray Eagle(R) STOL UAS
Oct 14, 2025 23:00 HKT/SGT
|
|
|
Kincora Advances the Historic Condobolin Mining Field
Oct 14, 2025 20:59 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
